A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Recruiting · NCT07027514 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-09-02 | NCT07027514 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ankyra Therapeutics, Inc | 2 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Barbara Ann Karmanos Cancer Hospital | Detroit | United States | 3 |
| Community Health Network | Indianapolis | United States | 5 |
| FirstHealth of the Carolinas | Pinehurst | United States | 7 |
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Mayo Clinic | Rochester | United States | 664 |
| Mayo Clinic | Jacksonville | United States | 122 |
| OSF Healthcare System; Saint Francis Medical Center | Peoria | United States | 1 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 63 |
| Thomas Jefferson University | Philadelphia | United States | 165 |
| University of Miami | Coral Gables | United States | 34 |
| Vanderbilt University | Nashville | United States | 51 |